2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.

Kim, K-I; Kim, S-R; Sasase, N; Taniguchi, M; Harada, S; Kinoshita, K; Kim, S-H; Akimoto, Y; Shikata, M; Kimura, N; Izawa, S; Ohtani, A; Nakao, K; Motojima, M; Kinoshita, M; Hirai, M; Ohzu, M; Hirooka, T; Nabeshima, S; Ishii, F; Tanaka, K; Hotta, H

Kim, K-I; Kim, S-R; Sasase, N; Taniguchi, M; Harada, S; Kinoshita, K; Kim, S-H; Akimoto, Y; Shikata, M; Kimura, N; Izawa, S; Ohtani, A; Nakao, K; Motojima, M; Kinoshita, M; Hirai, M; Ohzu, M; Hirooka, T; Nabeshima, S; Ishii, F; Tanaka, K; Hotta, H.

Affiliation

Kim KI; Department of Pharmacy, Kobe Asahi Hospital, Kobe, Japan.

J Clin Pharm Ther ; 31(5): 441-6, 2006 Oct.

Article in En | MEDLINE | ID: mdl-16958821

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Polyethylene Glycols / Ribavirin / 2',5'-Oligoadenylate Synthetase / Interferon-alpha / Hepatitis C, Chronic Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: J Clin Pharm Ther Journal subject: FARMACIA / TERAPEUTICA Year: 2006 Document type: Article Affiliation country: Japón Country of publication: Reino Unido

Search on Google

Add to My VHL

XML

PubMed Links